Mangoceuticals (MGRX) versus Its Rivals Head to Head Analysis

Mangoceuticals (NASDAQ:MGRX) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Mangoceuticals to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, earnings, valuation and risk.

Volatility and Risk

Mangoceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 4.14, indicating that their average stock price is 314% more volatile than the S&P 500.

Profitability

This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-816.62%	-48.14%	-36.60%

Analyst Recommendations

This is a summary of recent ratings for Mangoceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	0	0	0	0	N/A
Mangoceuticals Competitors	36	288	416	147	2.76

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 38.20%. Given Mangoceuticals’ competitors higher possible upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Mangoceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$730,000.00	-$9.21 million	-0.38
Mangoceuticals Competitors	$2.50 billion	$82.32 million	13.61

Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mangoceuticals competitors beat Mangoceuticals on 9 of the 10 factors compared.

Mangoceuticals Company Profile

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.